Dapagliflozin Versus Placebo on Left Ventricular Remodeling in Patients With Diabetes and Heart Failure: The REFORM Trial

Overview

Journal Diabetes Care

Specialty Endocrinology

Date 2020 Apr 5

PMID 32245746

Citations 65

Authors

Jagdeep S S Singh

Ify R Mordi

Keeran Vickneson

Amir Fathi

Peter T Donnan

Mohapradeep Mohan

Anna Maria J Choy

Stephen Gandy

Jacob George

Faisel Khan

Ewan R Pearson

J Graeme Houston

Allan D Struthers

Chim C Lang

Affiliations

Soon will be listed here.

Abstract

Objective: To determine the effects of dapagliflozin in patients with heart failure (HF) and type 2 diabetes mellitus (T2DM) on left ventricular (LV) remodeling using cardiac MRI.

Research Design And Methods: We randomized 56 patients with T2DM and HF with LV systolic dysfunction to dapagliflozin 10 mg daily or placebo for 1 year, on top of usual therapy. The primary end point was difference in LV end-systolic volume (LVESV) using cardiac MRI. Key secondary end points included other measures of LV remodeling and clinical and biochemical parameters.

Results: In our cohort, dapagliflozin had no effect on LVESV or any other parameter of LV remodeling. However, it reduced diastolic blood pressure and loop diuretic requirements while increasing hemoglobin, hematocrit, and ketone bodies. There was a trend toward lower weight.

Conclusions: We were unable to determine with certainty whether dapagliflozin in patients with T2DM and HF had any effect on LV remodeling. Whether the benefits of dapagliflozin in HF are due to remodeling or other mechanisms remains unknown.

Citing Articles

The comparative study of the efficacy of recombinant human brain natriuretic peptide combined with vasoactive medications for elderly patients with heart failure and hypotension receiving injections.

Meng R, Li X, Liu H, Yi Z, Han Y, Xie Q BMC Cardiovasc Disord. 2025; 25(1):185.

PMID: 40089700 DOI: 10.1186/s12872-025-04609-8.

Impact of SGLT2 inhibitors on cardiovascular outcomes and metabolic events in Chinese han patients with chronic heart failure.

Li F, Baheti R, Jin M, Xiong W, Duan J, Fang P Diabetol Metab Syndr. 2024; 16(1):299.

PMID: 39696647 PMC: 11657645. DOI: 10.1186/s13098-024-01553-z.

Effect of optimisation to contemporary HFrEF medical therapy with sacubitril/valsartan (Entresto) and dapaglifloziN on left Ventricular reverse remodelling as demonstrated by cardiac magnetic resonance (CMR) Imaging: the ENVI study.

Zheng A, Adam R, Peebles C, Harden S, Shambrook J, Abbas A Open Heart. 2024; 11(2.

PMID: 39622578 PMC: 11624772. DOI: 10.1136/openhrt-2024-002933.

Risk factors associated with SGLT2 inhibitor discontinuation in diabetic patients with heart failure.

Kim M, Heo S, Kim M, Park J, Bae S, Roh J PLoS One. 2024; 19(11):e0314305.

PMID: 39585835 PMC: 11588271. DOI: 10.1371/journal.pone.0314305.

Sodium glucose cotransporter 2 inhibitors in the management of heart failure: Veni, Vidi, and Vici.

Bhandari M, Pradhan A, Vishwakarma P, Singh A, Sethi R World J Cardiol. 2024; 16(10):550-563.

PMID: 39492976 PMC: 11525799. DOI: 10.4330/wjc.v16.i10.550.

References

Singh J, Fathi A, Vickneson K, Mordi I, Mohan M, Houston J . Research into the effect Of SGLT2 inhibition on left ventricular remodelling in patients with heart failure and diabetes mellitus (REFORM) trial rationale and design. Cardiovasc Diabetol. 2016; 15:97. PMC: 4946228. DOI: 10.1186/s12933-016-0419-0. View

Zelniker T, Wiviott S, Raz I, Im K, Goodrich E, Bonaca M . SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2018; 393(10166):31-39. DOI: 10.1016/S0140-6736(18)32590-X. View

Konstam M, Kramer D, Patel A, Maron M, Udelson J . Left ventricular remodeling in heart failure: current concepts in clinical significance and assessment. JACC Cardiovasc Imaging. 2011; 4(1):98-108. DOI: 10.1016/j.jcmg.2010.10.008. View

Kramer D, Trikalinos T, Kent D, Antonopoulos G, Konstam M, Udelson J . Quantitative evaluation of drug or device effects on ventricular remodeling as predictors of therapeutic effects on mortality in patients with heart failure and reduced ejection fraction: a meta-analytic approach. J Am Coll Cardiol. 2010; 56(5):392-406. PMC: 4523221. DOI: 10.1016/j.jacc.2010.05.011. View

Packer M . Heart Failure: The Most Important, Preventable, and Treatable Cardiovascular Complication of Type 2 Diabetes. Diabetes Care. 2017; 41(1):11-13. DOI: 10.2337/dci17-0052. View

Lam C, Chandramouli C, Ahooja V, Verma S . SGLT-2 Inhibitors in Heart Failure: Current Management, Unmet Needs, and Therapeutic Prospects. J Am Heart Assoc. 2019; 8(20):e013389. PMC: 6818035. DOI: 10.1161/JAHA.119.013389. View

Mordi I, Bezerra H, Carrick D, Tzemos N . The Combined Incremental Prognostic Value of LVEF, Late Gadolinium Enhancement, and Global Circumferential Strain Assessed by CMR. JACC Cardiovasc Imaging. 2015; 8(5):540-549. DOI: 10.1016/j.jcmg.2015.02.005. View

Mudaliar S, Alloju S, Henry R . Can a Shift in Fuel Energetics Explain the Beneficial Cardiorenal Outcomes in the EMPA-REG OUTCOME Study? A Unifying Hypothesis. Diabetes Care. 2016; 39(7):1115-22. DOI: 10.2337/dc16-0542. View

Mazer C, Hare G, Connelly P, Gilbert R, Shehata N, Quan A . Effect of Empagliflozin on Erythropoietin Levels, Iron Stores, and Red Blood Cell Morphology in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease. Circulation. 2019; 141(8):704-707. DOI: 10.1161/CIRCULATIONAHA.119.044235. View

10.

Ferrannini E, Baldi S, Frascerra S, Astiarraga B, Barsotti E, Clerico A . Renal Handling of Ketones in Response to Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 2 Diabetes. Diabetes Care. 2017; 40(6):771-776. DOI: 10.2337/dc16-2724. View

11.

McMurray J, Solomon S, Inzucchi S, Kober L, Kosiborod M, Martinez F . Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019; 381(21):1995-2008. DOI: 10.1056/NEJMoa1911303. View

12.

Mordi I, Jhund P, Gardner R, Payne J, Carrick D, Berry C . LGE and NT-proBNP identify low risk of death or arrhythmic events in patients with primary prevention ICDs. JACC Cardiovasc Imaging. 2014; 7(6):561-9. DOI: 10.1016/j.jcmg.2013.12.014. View